Capella Bioscience
Novel Target Therapeutic Antibodies

Capella Bioscience is a biotechnology company that employs proprietary technologies to discover, develop, and commercialize monoclonal antibody medicines (mAbs) to difficult and novel drug targets. Capella is developing a pipeline of novel mAbs against therapeutic targets in oncology and autoimmune disease. The company is located in Cambridge, UK and has relationships with several academic institutions, including the Sanford Burnham Prebys Medical Discovery Institute.


University
Sanford Burnham Prebys
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website